Renal Cell Carcinoma (RCC)
Conditions
Brief summary
To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.
Interventions
None listed
Sponsors
Second Xiangya Hospital of Central South University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma). * Contrast-enhanced CT scan was performed preoperatively.
Exclusion criteria
* Pure cystic clear cell renal cell carcinoma * Poor-quality CT images
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CT-based radiomics analysis for benign and malignant tumor differentiation | within 1 month | Histopathological diagnosis served as the gold standard, with tumors classified into: (1) Benign renal tumors: Including lipid-poor angiomyolipoma and renal oncocytoma; (2) Malignant renal tumors: Comprising clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma |
| CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC) | within 1 month | Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low grade ccRCC: Including WHO/ISUP grade 1-2 ccRCC; (2) high grade ccRCC: Including WHO/ISUP grade 3-4 ccRCC |
| CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC) | within 1 month | Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low T-stage RCC: Including T1-2 RCC; (2) high T-stage RCC: including T3-4 RCC |
Countries
China
Outcome results
None listed